Biomea Fusion's Stock Plummets After Price Target Cut — Bearish Retail Traders Speculate Next Moves Biomea Fusion is realigning its focus on diabetes and obesity programs, cutting 35% of its workforce and consolidating operations to reduce costs.
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday? Biomea Fusion's COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions.
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 1 and type 2 diabetes following a safety review, allowing the ongoing studies to resume.
BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024 BMEA stock results show that Biomea Fusion beat analyst estimates for earnings per share the second quarter of 2024.
Why Biomea Fusion (BMEA) Stock Is Down 60% Biomea Fusion shares are trading lower by 62.7% during Friday's session. The company received notice from the FDA that Its trials of BMF-219 have been placed on clinical hold.
Biomea Fusion Crashes 65% After FDA Puts Diabetes Treatment Studies On Hold The FDA cited concerns of liver toxicity, but the company says its drug has been generally well-tolerated.
Why Is Virax Biolabs (VRAX) Stock Down 15% Today? Virax Biolabs stock is down on Friday as shares of VRAX come off of a massive rally yesterday that didn't come with any news.
Why Is Biomea Fusion (BMEA) Stock Down 63% Today? Biomea Fusion stock is falling on Friday after investors learned of the FDA placing a clinical hold on its Phase I/II clinical trials.
